Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months.

This study has been completed.
Sponsor:
Collaborators:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sprim Advanced Life Sciences
Information provided by (Responsible Party):
Fonterra Research Centre
ClinicalTrials.gov Identifier:
NCT01724203
First received: November 7, 2012
Last updated: October 10, 2013
Last verified: October 2013
  Purpose

The purpose of this clinical trial is to evaluate the safety and effectiveness of 12-week probiotic supplementation on the incidence and duration of infectious episodes in infants aged 6 to 12 months.


Condition Intervention
Effect of Probiotics on Infections in Infants.
Dietary Supplement: Lactobacillus rhamnosus
Dietary Supplement: Bifidobacterium animalis subsp. lactis
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Health Services Research
Official Title: Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months: a Double-blind, Randomized, Placebo-controlled Study.

Resource links provided by NLM:


Further study details as provided by Fonterra Research Centre:

Primary Outcome Measures:
  • The proportion of subjects with one or more of confirmed bacterial or viral infections at any time during the study [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The primary endpoint of this clinical trial is the proportion of subjects with one or more of the following confirmed bacterial or viral infections at any time during the study: fever > 37.5ºC (axillary), upper respiratory tract infection, lower respiratory tract infection, pneumonia, strep throat, diarrhea, and otitis media.


Secondary Outcome Measures:
  • Cumulative days with infectious symptoms [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Cumulative number of days with infectious symptoms will be defined as the total number of days during the study on which a subject has symptoms of a confirmed infection. Confirmed infections that count toward the primary endpoint include: fever >37.5°C (axillary), upper respiratory tract infection, lower respiratory tract infection, pneumonia, strep throat, diarrhea, and otitis media.

  • Cumulative number of infectious episodes [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Cumulative number of infectious episodes will be defined as the total number of infectious episodes (defined as presence of one of more symptoms of a confirmed infection) experienced during the study. An infectious episode will be defined as a period when symptoms of a confirmed infection last for more than 24 hours and are followed by at least 3 days of no symptoms.

  • Stool frequency [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Parents will record the number of infant defecations each day in a diary during the 12-week supplementation period.

  • Stool Consistency [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Parents will rate the consistency of each infant bowel movement by using the Bristol Stool Scale Form. Parents will record stool consistency each day during the 12-week supplementation period.

  • Infant Characteristics Questionnaire [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The Infant Characteristic Questionnaire for infants approximately 6 months old (ICQ-6) measures parental perception of infant temperament, focusing on difficult temperament 8. The questionnaire is comprised of 24 items describing infant behavior. The parent or primary caregiver ranks each item on a 7-point scale, indicating the level of perceived difficulty in dealing with the described behavior. Four subscales have been identified through principal components analyses: Fussy/Difficult, Unadaptable, Dull, and Unpredictable.

  • Treatments for infectious episodes [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Treatments that are taken to alleviate infectious symptoms will be documented in a daily diary.

  • Adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Adverse events will be recorded in the daily diary and at study visits during the 12-week supplementation period.


Enrollment: 192
Study Start Date: December 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lactobacillus rhamnosus
Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
Dietary Supplement: Lactobacillus rhamnosus
Active Comparator: Bifidobacterium animalis subsp. lactis
Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
Dietary Supplement: Bifidobacterium animalis subsp. lactis
Placebo Comparator: Placebo
Placebo formula without probiotics at least three times daily for 12 weeks.
Dietary Supplement: Placebo

Detailed Description:

Probiotics are live bacteria that offer a health benefit to the host when administered via the diet in adequate amounts. Probiotic supplementation is safe for use in infants to the elderly and has demonstrated beneficial effects for a wide variety of health conditions such as acute diarrhea, antibiotic-associated diarrhea, allergies, and inflammatory bowel disease. The immune-enhancing benefits of probiotics are attractive, particularly for infants, a group that is particularly prone to a variety of infections, e.g. respiratory tract infection, strep throat, and diarrhea. Probiotic supplementation has been utilized in previous studies of childhood infections with promising results.

In this study, the safety and effectiveness of 12-week probiotic supplementation on the incidence and duration of infectious episodes in infants aged 6 to 12 months will be determined. The subjects will receive follow-on formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20), 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10), or placebo formula for at least three feeds per day for 12 weeks.

  Eligibility

Ages Eligible for Study:   6 Months to 12 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 6 to 12 months.
  • Known vaccination history.
  • Ability of the participant's parent or legal guardian to comprehend the full nature and purpose of the study including possible risks and side effects.
  • Parental or legal guardian's consent to the study and willing to comply with study procedures.

Exclusion Criteria:

  • Symptoms of any infection at screening.
  • History of ≥5 infections in the previous 2 months.
  • Lactose intolerance or unable to drink milk.
  • Leukopenia or leukocytosis.
  • Immunodeficient or use of immunosuppressive drugs.
  • Use of antibiotic and anti-inflammatory medications within the last 2 weeks.
  • Use of products containing prebiotics or probiotics within the last 2 weeks.
  • Use of low-lactose or lactose-free infant or follow-on formula within the last 2 weeks.
  • Hepatitis B or C.
  • Medications or supplements that may affect subject safety or confound study outcomes in the opinion of the investigator.
  • Medical conditions or diseases that may affect subject safety or confound study results in the opinion of the investigator.
  • Participation in another study with any investigational product within 3 months of screening.
  • Any other condition that, in the investigator's opinion, may preclude the subject's ability to safely complete the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01724203

Locations
China, Shanghai
Shanghai Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai, China, 200092
Sponsors and Collaborators
Fonterra Research Centre
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sprim Advanced Life Sciences
Investigators
Principal Investigator: Xiaoyang Sheng, Dr Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
  More Information

No publications provided

Responsible Party: Fonterra Research Centre
ClinicalTrials.gov Identifier: NCT01724203     History of Changes
Other Study ID Numbers: 111104-SUS-FON-ICP-MS
Study First Received: November 7, 2012
Last Updated: October 10, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by Fonterra Research Centre:
Probiotics for infants
Bacterial and viral infections in infants

Additional relevant MeSH terms:
Virus Diseases

ClinicalTrials.gov processed this record on July 22, 2014